We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+10.71%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$116M
AUM Growth
+$4.15M
Cap. Flow
-$8.23M
Cap. Flow %
-7.12%
Top 10 Hldgs %
50.71%
Holding
66
New
3
Increased
–
Reduced
29
Closed
2
Avg Time Held Equity + Options
6.2 quarters
Top 10 Avg Time Held Equity + Options
3.1 quarters
Top 20 Avg Time Held Equity + Options
4.5 quarters
Avg Time Held Equity only
6.5 quarters
Top 10 Avg Time Held Equity only
4 quarters
Top 20 Avg Time Held Equity only
5.6 quarters

Top Buys

Rank Stock Value
1
PRQR icon
ProQR Therapeutics
PRQR
+$1.1M
2
KYNB icon
Kyntra Bio
KYNB
+$222K

Top Sells

Rank Stock Value
1
LABU icon
Direxion Daily S&P Biotech Bull 3X ETF
LABU
+$1.37M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$552K
3
NKTR icon
Nektar Therapeutics
NKTR
+$483K
4
JUNO
Juno Therapeutics, Inc.
JUNO
+$456K
5
NBIX icon
Neurocrine Biosciences
NBIX
+$371K

Sector Composition

Rank Sector Weight
1 Healthcare 67.33%
2 Miscellaneous 32.4%
3 Real Estate 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
SAGE icon
1
PUT
DELISTED
Sage Therapeutics
SAGE
$11.7M 10.12%
+71,000
New +$6.88M
2017 Q4
0 quarters
BIB icon
2
ProShares Ultra NASDAQ Biotechnology
BIB
$91.6M
$7.32M 6.33%
130,500
– –
2016 Q3
5 quarters
XBI icon
3
State Street SPDR S&P Biotech ETF
XBI
$10B
$5.52M 4.77%
65,000
– –
2016 Q2
6 quarters
BMY icon
4
Bristol-Myers Squibb
BMY
$117B
$5.51M 4.77%
90,000
– –
2015 Q3
9 quarters
NKTR icon
5
Nektar Therapeutics
NKTR
$1.37B
$5.5M 4.76%
6,138
-817
-12% -$483K
2014 Q4
12 quarters
ALNY icon
6
Alnylam Pharmaceuticals
ALNY
$30.5B
$5.47M 4.73%
43,064
-4,395
-9% -$552K
2014 Q4
12 quarters
MRK icon
7
Merck
MRK
$358B
$4.71M 4.07%
87,718
– –
2015 Q3
9 quarters
RXDX
8
DELISTED
Ignyta, Inc.
RXDX
$4.55M 3.94%
170,500
– –
2017 Q2
2 quarters
ALXN
9
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$4.19M 3.62%
35,000
– –
2017 Q1
3 quarters
AZN icon
10
AstraZeneca
AZN
$246B
$4.16M 3.6%
60,000
– –
2015 Q2
10 quarters
PFE icon
11
Pfizer
PFE
$162B
$4.07M 3.52%
118,364
– –
2016 Q1
7 quarters
IBB icon
12
iShares Biotechnology ETF
IBB
$10.5B
$4M 3.46%
37,500
– –
2016 Q2
6 quarters
BMY icon
13
CALL
Bristol-Myers Squibb
BMY
$117B
$2.76M 2.39%
45,000
– –
2016 Q3
5 quarters
VRTX icon
14
Vertex Pharmaceuticals
VRTX
$129B
$2.49M 2.16%
16,639
-1,635
-9% -$242K
2014 Q4
12 quarters
ALKS icon
15
Alkermes
ALKS
$6.74B
$2.4M 2.07%
43,763
-4,481
-9% -$229K
2014 Q4
12 quarters
MTD icon
16
Mettler-Toledo International
MTD
$31.3B
$2.23M 1.93%
3,594
– –
2014 Q4
12 quarters
GSK icon
17
GSK
GSK
$94.2B
$2.13M 1.84%
48,000
– –
2016 Q2
6 quarters
ILMN icon
18
Illumina
ILMN
$40.9B
$2.12M 1.84%
9,989
-1,561
-14% -$321K
2014 Q4
12 quarters
IONS icon
19
Ionis Pharmaceuticals
IONS
$7.34B
$1.98M 1.71%
39,388
-4,795
-11% -$263K
2014 Q4
12 quarters
SGEN
20
DELISTED
Seagen Inc. Common Stock
SGEN
$1.91M 1.65%
35,668
-5,595
-14% -$327K
2014 Q4
12 quarters
BIIB icon
21
Biogen
BIIB
$34.6B
$1.84M 1.6%
5,793
-894
-13% -$287K
2014 Q4
12 quarters
QGEN icon
22
Qiagen
QGEN
$9.32B
$1.75M 1.51%
53,231
-7,522
-12% -$259K
2017 Q1
3 quarters
INCY icon
23
Incyte
INCY
$22.8B
$1.74M 1.5%
18,318
-1,830
-9% -$191K
2014 Q4
12 quarters
AMGN icon
24
Amgen
AMGN
$225B
$1.73M 1.49%
9,924
-1,482
-13% -$262K
2014 Q4
12 quarters
AGIO icon
25
Agios Pharmaceuticals
AGIO
$1.85B
$1.64M 1.42%
28,704
-4,643
-14% -$292K
2015 Q3
9 quarters
1
2 3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q4 2017 Portfolio in Review

As of Q4 2017, Opus Point Partners Management held 66 positions worth $116M, up 3.7% from $111M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Opus Point Partners Management withdrew a net $8.23M in Q4 2017, closing 2 positions and reducing 29 holdings. Its most notable exit was Direxion Daily S&P Biotech Bull 3X ETF, an estimated $1.37M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, down from 74% a quarter earlier, followed by Miscellaneous and Real Estate.

Against the trend, Opus Point Partners Management opened a new position in ProQR Therapeutics worth $992K.

  • Opus Point Partners Management's largest Q4 2017 buy was ProQR Therapeutics: 307,692 shares worth $992K.
  • Opus Point Partners Management's biggest Q4 2017 reduction was Alnylam Pharmaceuticals, cutting an estimated $552K.
  • Opus Point Partners Management fully exited Direxion Daily S&P Biotech Bull 3X ETF in Q4 2017, selling an estimated $1.37M.
  • Opus Point Partners Management's ten largest holdings make up 51% of its $116M portfolio in Q4 2017.
  • Opus Point Partners Management opened 3 new positions and closed 2 in Q4 2017.
  • Opus Point Partners Management's portfolio value rose 3.7% quarter-over-quarter to $116M.

Based on Opus Point Partners Management's 13F filing for Q4 2017, filed 14 Feb 2018.